Total Payments
$23,380
2024 Payments
$2,515
Companies
64
Transactions
946
Medicare Patients
4,818
Medicare Billing
$455,410
Payment Breakdown by Category
Food & Beverage$16,913 (72.3%)
Research$4,458 (19.1%)
Travel$1,293 (5.5%)
Gifts$480.00 (2.1%)
Consulting$150.00 (0.6%)
Education$85.85 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $16,913 | 891 | 72.3% |
| Unspecified | $4,458 | 42 | 19.1% |
| Travel and Lodging | $1,293 | 5 | 5.5% |
| Gift | $480.00 | 2 | 2.1% |
| Consulting Fee | $150.00 | 1 | 0.6% |
| Education | $85.85 | 5 | 0.4% |
Payments by Type
General
$18,922
904 transactions
Research
$4,458
42 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $5,399 | 174 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,396 | 137 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,768 | 23 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,315 | 74 | $0 (2024) |
| AstraZeneca UK Limited | $1,205 | 5 | $0 (2022) |
| Novo Nordisk Inc | $913.59 | 68 | $0 (2024) |
| Lilly USA, LLC | $668.27 | 40 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $650.41 | 46 | $0 (2024) |
| Amgen Inc. | $550.32 | 36 | $0 (2024) |
| Resmed Corp | $519.26 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,515 | 110 | GlaxoSmithKline, LLC. ($479.24) |
| 2023 | $3,026 | 115 | AstraZeneca Pharmaceuticals LP ($1,309) |
| 2022 | $3,322 | 108 | AstraZeneca UK Limited ($1,205) |
| 2021 | $1,804 | 113 | AstraZeneca Pharmaceuticals LP ($352.52) |
| 2020 | $4,036 | 108 | Takeda Pharmaceuticals U.S.A., Inc. ($1,720) |
| 2019 | $3,365 | 150 | GlaxoSmithKline, LLC. ($699.01) |
| 2018 | $2,160 | 132 | GlaxoSmithKline, LLC. ($537.09) |
| 2017 | $3,152 | 110 | GlaxoSmithKline, LLC. ($1,553) |
All Payment Transactions
946 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $31.54 | General |
| Category: Cardiology | ||||||
| 12/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: Cardio-renal | ||||||
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $27.77 | General |
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $18.98 | General |
| Category: HFCWO | ||||||
| 11/27/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: RESPIRATORY | ||||||
| 11/05/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/31/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $33.56 | General |
| Category: NEUROLOGY | ||||||
| 10/30/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: VACCINES | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.07 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $19.27 | General |
| 10/08/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $27.95 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $76.80 | General |
| Category: RESPIRATORY | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $27.73 | General |
| Category: VACCINE | ||||||
| 09/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: Immunology | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $106.71 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | Takeda Pharmaceuticals U.S.A., Inc. | $1,708 | 20 |
| A 24 month double blind randomised parallel group study to determine the effect of Anoro on symptoms vs Tiotropium | GlaxoSmithKline, LLC. | $1,228 | 7 |
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | GlaxoSmithKline, LLC. | $1,167 | 13 |
| A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy | Jazz Pharmaceuticals Inc. | $196.61 | 1 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $159.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 963 | 1,341 | $292,887 | $89,115 |
| 2022 | 19 | 1,146 | 1,761 | $383,163 | $116,920 |
| 2021 | 17 | 1,213 | 1,768 | $369,316 | $120,738 |
| 2020 | 20 | 1,496 | 1,961 | $413,163 | $128,637 |
Total Patients
4,818
Total Services
6,831
Medicare Billing
$455,410
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 166 | 287 | $71,463 | $24,945 | 34.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 68 | 270 | $47,790 | $16,524 | 34.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 64 | 70 | $34,540 | $9,385 | 27.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 76 | 76 | $29,260 | $8,179 | 28.0% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 50 | 50 | $19,300 | $4,511 | 23.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $8,421 | $3,545 | 42.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 78 | 80 | $12,720 | $3,382 | 26.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 31 | $7,905 | $2,854 | 36.1% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 108 | 118 | $11,210 | $2,771 | 24.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 20 | $7,040 | $2,645 | 37.6% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 78 | 80 | $9,760 | $2,609 | 26.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 40 | $7,040 | $2,443 | 34.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 22 | 22 | $8,888 | $2,005 | 22.6% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 99 | 102 | $10,914 | $1,969 | 18.0% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Facility | 2023 | 23 | 23 | $4,600 | $747.56 | 16.3% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 21 | 32 | $896.00 | $456.32 | 50.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 19 | 19 | $1,140 | $143.26 | 12.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 181 | 326 | $80,755 | $29,481 | 36.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 92 | 501 | $88,677 | $27,388 | 30.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 77 | 84 | $41,580 | $12,984 | 31.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 109 | 109 | $41,905 | $12,734 | 30.4% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2022 | 59 | 59 | $22,774 | $5,457 | 24.0% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2022 | 44 | 46 | $18,584 | $4,419 | 23.8% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 97 | 99 | $15,741 | $4,161 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 53 | $9,328 | $3,416 | 36.6% |
About Dr. Anup Banerjee, M.D
Dr. Anup Banerjee, M.D is a Pulmonary Disease healthcare provider based in Gastonia, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740213263.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anup Banerjee, M.D has received a total of $23,380 in payments from pharmaceutical and medical device companies, with $2,515 received in 2024. These payments were reported across 946 transactions from 64 companies. The most common payment nature is "Food and Beverage" ($16,913).
As a Medicare-enrolled provider, Banerjee has provided services to 4,818 Medicare beneficiaries, totaling 6,831 services with total Medicare billing of $455,410. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Gastonia, NC
- Active Since 07/08/2006
- Last Updated 05/01/2008
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1740213263
Products in Payments
- ANORO (Drug) $1,720
- BREZTRI (Drug) $1,576
- NUCALA (Biological) $1,451
- TRELEGY ELLIPTA (Drug) $1,109
- DUPIXENT (Biological) $648.33
- XARELTO (Drug) $588.60
- STIOLTO RESPIMAT (Drug) $530.98
- AirSense (Device) $480.00
- SYMBICORT (Drug) $464.06
- Arikayce (Drug) $423.51
- FASENRA (Drug) $375.31
- OFEV (Drug) $369.90
- OPSUMIT (Drug) $358.18
- Ozempic (Drug) $342.95
- ACTHAR (Biological) $307.86
- ANORO ELLIPTA (Drug) $295.97
- AREXVY (Drug) $287.76
- Kerendia (Drug) $262.03
- ZERBAXA (Drug) $257.85
- Aimovig (Biological) $250.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Gastonia
Mikell Jarratt, M.d, M.D
Pulmonary Disease — Payments: $49,942
Pulmonary Disease $49,942
Emeka Eziri, Md, MD
Pulmonary Disease — Payments: $16,653
Pulmonary Disease $16,653
Kimtuyen Nguyen, Md, MD
Pulmonary Disease — Payments: $7,621
Pulmonary Disease $7,621
Narayan Neupane, Md, MD
Pulmonary Disease — Payments: $6,097
Pulmonary Disease $6,097
Dr. Laura Peno-Green, Md, MD
Pulmonary Disease — Payments: $3,485
Pulmonary Disease $3,485
Wesley Golding, Agacnp, AGACNP
Pulmonary Disease — Payments: $375.13
Pulmonary Disease $375.13